Low Leverage / No DebtHaving no recorded debt is a durable financial strength: it reduces fixed interest costs and preserves operational flexibility. Over the next several months this lowers default risk and gives management optionality to prioritize R&D or seek non-debt funding without immediate interest burdens.

Focused NRT Product PipelineA focused business model centered on nicotine replacement therapy (NIC-101) creates a clear strategic roadmap and concentrated R&D efforts. This specialization supports regulatory focus, potential IP depth and targeted commercialization plans, making competitive positioning more durable vs. scattered pipelines.

Lean Operating FootprintA very small headcount implies a low fixed-cost base and operational nimbleness, which can materially extend runway versus larger peers. Over a multi-month horizon this helps conserve cash, allows focused spending on clinical milestones, and reduces near-term dilution pressure if managed prudently.

Bears Say

Sharp Revenue DeclineA sustained ~68% drop in trailing revenue signals weakened commercial traction or disrupted sales channels. Lower recurring top-line undermines scale economics and margin recovery, increasing reliance on external funding and heightening execution risk for product development and market roll-out over the next several months.

Large, Persistent Cash BurnDeep negative operating and free cash flows are a structural concern: they erode cash reserves rapidly and force repeated capital raises or strategic cuts. This lasting cash-burn profile constrains investment in trials or commercialization and raises dilution and refinancing risk absent material changes to operations or funding.

Negative Shareholders' EquityEquity turning negative reflects accumulated losses and weakens the balance sheet cushion. This durable impairment limits access to debt, can reduce counterparty confidence and heighten insolvency risk absent fresh capital, constraining strategic options and increasing dependence on external funding sources.

ERMA FAQ

What was Enorama Pharma AB’s price range in the past 12 months?

Enorama Pharma AB lowest stock price was kr0.40 and its highest was kr3.58 in the past 12 months.

What is Enorama Pharma AB’s market cap?

Enorama Pharma AB’s market cap is kr50.27M.

When is Enorama Pharma AB’s upcoming earnings report date?

Enorama Pharma AB’s upcoming earnings report date is May 20, 2026 which is in 72 days.

How were Enorama Pharma AB’s earnings last quarter?

Currently, no data Available

Is Enorama Pharma AB overvalued?

According to Wall Street analysts Enorama Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Enorama Pharma AB pay dividends?

Enorama Pharma AB does not currently pay dividends.

What is Enorama Pharma AB’s EPS estimate?

Enorama Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Enorama Pharma AB have?

Enorama Pharma AB has 74,588,684 shares outstanding.

What happened to Enorama Pharma AB’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Enorama Pharma AB?

Currently, no hedge funds are holding shares in SE:ERMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Enorama Pharma AB

Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. It offers nicotine chewing gum for smoking cessation and medical cannabis chewing gums for non-pharma applications, as well as for other applications, such as oromucosal drug delivery and allergic rhinitis. The company is based in Malmö, Sweden.